Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN Q2 2025 earnings

Reported August 5, 2025 · After market close

Revenue$165.5MMiss by $2.8M
EPS$0.91Beat by $0.44
Revenue estimate$168.2M
EPS estimate$0.47

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$205.3M
EPS estimate$0.42

Financials

Q2 2025

Income statement

See full
Revenue$165.5M-1.7%
Gross profit$148.6M-1.2%
Operating income$12.1M-46.2%
Net income$22.5M+13.0%
EPS (diluted)$0.40+11.1%

Balance sheet

See full
Cash & equivalents$144.7M+178%
Total debt$31.8M-20.5%
Total equity$1.1B+11.1%
Total assets$1.4B+5.1%

Cash flow

See full
Operating cash flow$58.5M+64.3%
CapEx$455.0K+611%
Free cash flow$58.1M+63.3%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.77B+21.0%
Enterprise value$1.66B+14.2%
P/E27.5×-252×
P/S2.7×+0.3×

Profitability

See full
Gross margin88.5%+0.2pp
Operating margin9.6%+5.4pp
Net margin9.7%+8.9pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity6.4%+5.8pp
Debt / equity0×0.0×
Current ratio2.6×+0.7×

Segments

By product

See full
Qelbree$77.5M+30.6%
GOCOVRI$36.7M+15.6%
APOKYN$12.8M-25.9%
Oxtellar XR$11.6M-60.6%
Trokendi XR$11.2M-34.5%

By segment

See full
Reportable Segment$165.5M-1.7%

Versus estimates

Revenue

Q1 2026$207.7MBeat by $14.8MQ4 2025$211.6MBeat by $16.4MQ3 2025$192.1MMiss by $2.6M
Q2 2025$165.5MMiss by $2.8M
Q1 2025$149.8MBeat by $1.9MQ4 2024$174.2MBeat by $18.9M

Diluted EPS

Q1 2026$0.59Beat by $0.31Q4 2025$0.92Beat by $0.64Q3 2025$1.01Beat by $0.19
Q2 2025$0.91Beat by $0.44
Q1 2025$0.42Beat by $0.04Q4 2024$0.75Beat by $0.29

Ask the moment Supernus Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Supernus Pharmaceuticals report Q2 2025 earnings?
Supernus Pharmaceuticals (SUPN) reported Q2 2025 earnings on August 5, 2025 after market close.
What were Supernus Pharmaceuticals's Q2 2025 revenue and EPS?
Supernus Pharmaceuticals reported revenue of $165.5M and eps of $0.91 for Q2 2025.
Did Supernus Pharmaceuticals beat estimates in Q2 2025?
Revenue missed the consensus estimate of $168.2M by $2.8M. EPS beat the consensus estimate of $0.47 by $0.44.
How did Supernus Pharmaceuticals's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 1.7% from $168.3M a year earlier and eps grew 152.8% from $0.36.
Where can I find Supernus Pharmaceuticals's Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001356576-25-000055) directly on SEC EDGAR. The filing index links above go to sec.gov.